JP2023510218A - 長時間作用型ｇｌｐ－１化合物 - Google Patents

長時間作用型ｇｌｐ－１化合物 Download PDF

Info

Publication number
JP2023510218A
JP2023510218A JP2022540870A JP2022540870A JP2023510218A JP 2023510218 A JP2023510218 A JP 2023510218A JP 2022540870 A JP2022540870 A JP 2022540870A JP 2022540870 A JP2022540870 A JP 2022540870A JP 2023510218 A JP2023510218 A JP 2023510218A
Authority
JP
Japan
Prior art keywords
human insulin
γglu
desb30 human
eicosanediacyl
docosanediacyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540870A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021136303A5 (https=
JP2023510218A5 (https=
Inventor
ガン，ジョォンルー
チェン，ウェイ
ジャン，イイニン
シュエ，ファンカイ
ツァイ，リンギュ
ニィウ，ジァンホン
ム，ビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of JP2023510218A publication Critical patent/JP2023510218A/ja
Publication of JPWO2021136303A5 publication Critical patent/JPWO2021136303A5/ja
Publication of JP2023510218A5 publication Critical patent/JP2023510218A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
  • Pens And Brushes (AREA)
JP2022540870A 2019-12-30 2020-12-29 長時間作用型ｇｌｐ－１化合物 Pending JP2023510218A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911397405.2 2019-12-30
CN201911397405 2019-12-30
CN202011053306.5 2020-09-29
CN202011053306 2020-09-29
PCT/CN2020/141057 WO2021136303A1 (zh) 2019-12-30 2020-12-29 长效glp-1化合物

Publications (3)

Publication Number Publication Date
JP2023510218A true JP2023510218A (ja) 2023-03-13
JPWO2021136303A5 JPWO2021136303A5 (https=) 2025-10-27
JP2023510218A5 JP2023510218A5 (https=) 2025-10-27

Family

ID=76687327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540870A Pending JP2023510218A (ja) 2019-12-30 2020-12-29 長時間作用型ｇｌｐ－１化合物

Country Status (10)

Country Link
US (2) US20240239859A1 (https=)
EP (1) EP4086277A4 (https=)
JP (1) JP2023510218A (https=)
KR (1) KR20220119731A (https=)
CN (5) CN119529057A (https=)
AU (1) AU2020418207A1 (https=)
BR (1) BR112022013042A2 (https=)
CA (1) CA3166496A1 (https=)
MX (1) MX2022008139A (https=)
WO (1) WO2021136303A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020417892A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
CN119529057A (zh) * 2019-12-30 2025-02-28 甘李药业股份有限公司 长效glp-1化合物
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4360645A4 (en) * 2021-06-25 2025-09-10 Gan & Lee Pharmaceuticals Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING A GLP-1 COMPOUND
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
CA3237796A1 (en) * 2021-11-12 2023-05-19 Zhenbin Li Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
CN118574842A (zh) * 2022-01-28 2024-08-30 甘李药业股份有限公司 酰化胰岛素
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
EP4722236A1 (en) * 2023-05-24 2026-04-08 The United Bio-Technology (Hengqin) Co., Ltd. Insulin derivative and use thereof
WO2025005743A1 (ko) * 2023-06-30 2025-01-02 주식회사 휴온스랩 Glp 유사체를 유효성분으로 포함하는 비만 예방 또는 치료용 약학적 조성물
WO2025098415A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于降糖的glp-1化合物
WO2025098416A1 (zh) * 2023-11-06 2025-05-15 甘李药业股份有限公司 用于减肥的glp-1化合物
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
WO2025098502A1 (zh) * 2023-11-08 2025-05-15 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
TW202529797A (zh) * 2023-12-12 2025-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｇｌｐ－１類似物治療代謝疾病的方法及醫藥用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097537A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Acylated glp-1 compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
MXPA06015049A (es) * 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
EP2178910B1 (en) * 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2009030774A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Truncated glp-1 derivatives and their therapeutical use
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN102037008B (zh) * 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
US8788849B2 (en) * 2011-02-28 2014-07-22 Sandisk Technologies Inc. Method and apparatus for protecting cached streams
HRP20251088T1 (hr) * 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
MX2018002223A (es) * 2015-08-25 2018-03-23 Novo Nordisk As Derivados de insulina novedosos y usos medicos de los mismos.
EP3463429A4 (en) * 2016-05-24 2020-07-22 Merck Sharp & Dohme Corp. PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES
TWI700091B (zh) * 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
AU2020417892A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Insulin derivative
CN119529057A (zh) * 2019-12-30 2025-02-28 甘李药业股份有限公司 长效glp-1化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097537A2 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Acylated glp-1 compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JESPER LAU ET AL.: ""Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 18, JPN6025002575, 11 September 2015 (2015-09-11), pages 7370 - 7380, ISSN: 0005753482 *
JIA YING CHEANG ET AL.: ""Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities be", CHEMMEDCHEM, vol. 13, no. 7, JPN6025002577, 28 February 2018 (2018-02-28), pages 662 - 671, ISSN: 0005753484 *
LOTTE BJERRE KNUDSEN ET AL.: ""The Discovery and Development of Liraglutide and Semaglutide"", FRONTIERS IN ENDOCRINOLOGY, vol. 10, JPN6025002576, 12 April 2019 (2019-04-12), pages 1 - 32, ISSN: 0005753483 *
TAMER COSKUN ET AL.: ""LY3298176, a novel dual GIP and GLP-1 receptoragonist for the treatment of type 2 diabetes mellitu", MOLECULAR METABOLISM, vol. 18, JPN6025002578, December 2018 (2018-12-01), pages 3 - 14, ISSN: 0005753485 *

Also Published As

Publication number Publication date
CN119060163A (zh) 2024-12-03
KR20220119731A (ko) 2022-08-30
WO2021136303A1 (zh) 2021-07-08
CN114901680B (zh) 2024-09-27
MX2022008139A (es) 2022-10-03
CN119060162A (zh) 2024-12-03
US20250011385A1 (en) 2025-01-09
CA3166496A1 (en) 2021-07-08
CN119529057A (zh) 2025-02-28
EP4086277A4 (en) 2024-02-14
AU2020418207A1 (en) 2022-08-25
CN119060161A (zh) 2024-12-03
EP4086277A1 (en) 2022-11-09
US20240239859A1 (en) 2024-07-18
BR112022013042A2 (pt) 2022-10-18
CN114901680A (zh) 2022-08-12

Similar Documents

Publication Publication Date Title
JP2023510218A (ja) 長時間作用型ｇｌｐ－１化合物
US20250032589A1 (en) Insulin Derivative
US20250340610A1 (en) Acylated insulin
JPWO2021136303A5 (https=)
JPWO2021136296A5 (https=)
JPWO2021136293A5 (https=)
EA050234B1 (ru) Препараты glp-1 длительного действия
HK40115534A (zh) 长效glp-1化合物
EA050813B1 (ru) Производное инсулина
HK40109784A (zh) 胰岛素衍生物
EA050726B1 (ru) Производное инсулина
HK40070502A (zh) 胰岛素衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316